French animal genetics firm Groupe Grimaud has secured an investment of 40 million Euros from the FSI fund. The investment will infuse capital into the company’s Vivalis subsidiary. The Grimaud family will remain the majority owner of the firm and FSI will be a long-term, key shareholder.


The investment is expected to boost development of Vivalis’ biopharmacy business in multi-species animal genetics, and aid global expansion, particularly in South America and Asia.